Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
15.26 (1y: -20%)
Market Cap 747 M P/E(ttm) 10.10
Enterprise Value 278.19 M P/B 3.80
AUXL- NAS (USA)
Auxilium Pharmaceuticals, Inc.
Not Rated
Top Ranked Predictable Companies
$15.26
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry		 vs
history
Cash to Debt No Debt
AUXL's Cash to Debt is ranked higher than
69% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.36 vs. AUXL: No Debt )
AUXL' s 10-Year Cash to Debt Range
Min: 2.72   Max: 15218
Current: No Debt
2.72
15218
Equity to Asset 0.611
AUXL's Equity to Asset is ranked lower than
73% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.52 vs. AUXL: 0.611 )
AUXL' s 10-Year Equity to Asset Range
Min: -1.32   Max: 0.61
Current: 0.61
-1.32
0.61
Interest Coverage No Debt
AUXL's Interest Coverage is ranked higher than
54% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10000.00 vs. AUXL: No Debt )
AUXL' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 5
Z-Score: 1.76
M-Score: -1.79
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry		 vs
history
Operating margin (%) 21.60
AUXL's Operating margin (%) is ranked lower than
82% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.70 vs. AUXL: 21.60 )
AUXL' s 10-Year Operating margin (%) Range
Min: -335.4   Max: 21.6
Current: 21.6
-335.4
21.6
Net-margin (%) 21.7
AUXL's Net-margin (%) is ranked lower than
81% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. AUXL: 21.7 )
AUXL' s 10-Year Net-margin (%) Range
Min: -327.3   Max: 21.7
Current: 21.7
-327.3
21.7
ROE (%) 43
AUXL's ROE (%) is ranked lower than
85% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. AUXL: 43 )
AUXL' s 10-Year ROE (%) Range
Min: -131.3   Max: 43
Current: 43
-131.3
43
ROA (%) 26.3
AUXL's ROA (%) is ranked lower than
83% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.00 vs. AUXL: 26.3 )
AUXL' s 10-Year ROA (%) Range
Min: -59.9   Max: 26.3
Current: 26.3
-59.9
26.3
ROC (Joel Greenblatt) (%) 548.50
AUXL's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.40 vs. AUXL: 548.50 )
AUXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1463.3   Max: 548.5
Current: 548.5
-1463.3
548.5
Revenue Growth (%) 20.8
AUXL's Revenue Growth (%) is ranked higher than
93% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.20 vs. AUXL: 20.8 )
AUXL' s 10-Year Revenue Growth (%) Range
Min: -38.7   Max: 20.8
Current: 20.8
-38.7
20.8
ยป AUXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

AUXL Guru Trades in Q2 2012

Chuck Royce 50,000 sh (New)
Pioneer Investments 342,140 sh (+77.8%)
Jim Simons 611,100 sh (+58.15%)
Columbia Wanger 4,323,500 sh (-0.02%)
Steven Cohen 69,593 sh (-81.66%)
» More
Q3 2012

AUXL Guru Trades in Q3 2012

Paul Tudor Jones 20,100 sh (New)
Chuck Royce 312,000 sh (+524%)
Steven Cohen 148,239 sh (+113.01%)
Jim Simons 939,191 sh (+53.69%)
Columbia Wanger 4,323,500 sh (unchged)
Pioneer Investments 236,101 sh (-30.99%)
» More
Q4 2012

AUXL Guru Trades in Q4 2012

Chuck Royce 312,000 sh (unchged)
Pioneer Investments Sold Out
Jim Simons 859,100 sh (-8.53%)
Paul Tudor Jones 15,800 sh (-21.39%)
Columbia Wanger 2,443,758 sh (-43.48%)
Steven Cohen 37,304 sh (-74.84%)
» More
Q1 2013

AUXL Guru Trades in Q1 2013

Steven Cohen 591,501 sh (+1485.62%)
Paul Tudor Jones 31,100 sh (+96.84%)
Columbia Wanger Sold Out
Chuck Royce Sold Out
Jim Simons 499,500 sh (-41.86%)
» More
» Details

Insider Trades

Latest Guru Trades with AUXL

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-12-31 Sold Out 0.06%$14.21 - $19.93 $ 15.24-9%0
George Soros 2011-09-30 New Buy0.06%$13.95 - $20.84 $ 15.24-11%250000
Premium More recent guru trades are included for Premium Members only!!

Ratios

vs
industry		 vs
history
P/E(ttm) 10.10
AUXL's P/E(ttm) is ranked lower than
83% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.76 vs. AUXL: 10.10 )
AUXL' s 10-Year P/E(ttm) Range
Min: 9.68   Max: 11.47
Current: 10.1
9.68
11.47
P/B 3.80
AUXL's P/B is ranked lower than
80% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. AUXL: 3.80 )
AUXL' s 10-Year P/B Range
Min: 1.86   Max: 66.17
Current: 3.8
1.86
66.17
P/S 2.00
AUXL's P/S is ranked lower than
59% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.32 vs. AUXL: 2.00 )
AUXL' s 10-Year P/S Range
Min: 0.45   Max: 15.15
Current: 2
0.45
15.15
EV-to-EBIT 3.4
AUXL's EV-to-EBIT is ranked higher than
96% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.70 vs. AUXL: 3.4 )
AUXL' s 10-Year EV-to-EBIT Range
Min: 3.3   Max: 9.6
Current: 3.4
3.3
9.6

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 25.3
AUXL's Price/Net Cash is ranked lower than
78% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. AUXL: 25.3 )
AUXL' s 10-Year Price/Net Cash Range
Min: 3.8   Max: 34.5
Current: 25.3
3.8
34.5
Price/Net Current Asset Value 13.9
AUXL's Price/Net Current Asset Value is ranked higher than
91% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.20 vs. AUXL: 13.9 )
AUXL' s 10-Year Price/Net Current Asset Value Range
Min: 10.3   Max: 90.9
Current: 13.9
10.3
90.9
Price/Tangible Book 3.8
AUXL's Price/Tangible Book is ranked higher than
95% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.40 vs. AUXL: 3.8 )
AUXL' s 10-Year Price/Tangible Book Range
Min: 2.3   Max: 33.5
Current: 3.8
2.3
33.5
Price/Median PS Value 0.4
AUXL's Price/Median PS Value is ranked higher than
76% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.70 vs. AUXL: 0.4 )
AUXL' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 2.4
Current: 0.4
0.1
2.4
Price/Graham Number 1.2
AUXL's Price/Graham Number is ranked lower than
81% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. AUXL: 1.2 )
AUXL' s 10-Year Price/Graham Number Range
Min: 1.5   Max: 1.5
Current: 1.2
Earnings Yield (Greenblatt) 29.30
AUXL's Earnings Yield (Greenblatt) is ranked lower than
73% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. AUXL: 29.30 )
AUXL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 10.5   Max: 30.5
Current: 29.3
10.5
30.5
Forward Rate of Return (Yacktman) -1.22
AUXL's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.82 vs. AUXL: -1.22 )
AUXL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.8   Max: -1.6
Current: -1.22
-1.8
-1.6

Business Description

Auxilium Pharmaceuticals, Inc. incorporated in the state of Delaware. The company is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. It is currently market two products: Testim testosterone gel and XIAFLEX (collagenase clostridium histolyticum). Testim is a proprietary, topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism. Hypogonadism is defined as reduced or absent secretion of testosterone which can lead to symptoms such as low energy, loss of libido, and adverse changes in body composition, irritability and poor concentration. XIAFLEX is a proprietary, injectable collagenase enzyme approved by the United States ('U.S') Food and Drug Administration ('FDA') for the treatment of Dupuytren's contracture ('Dupuytren's') in adult patients with a palpable cord. Its current product pipeline includes: Phase III- XIAFLEX for the treatment of Peyronie's with top-line data expected late in the second quarter of 2012; Phase IIa: XIAFLEX for the treatment of Adhesive Capsulitis ('Frozen Shoulder syndrome') with top-line data expected in the first half of 2013; Phase Ib: XIAFLEX for the treatment of edematous fibrosclerotic panniculopathy ('cellulite') with top-line data expected in the fourth quarter of 2012. The company sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors and chain drug stores who generally sell products to retail pharmacies, hospitals and other institutional customers. It is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws, false claims laws and physician self-referral laws.
Company Website
SEC Reports
Industry: Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX
Traded in other countries:FEJ.Germany
ยป More Articles for AUXL

Headlines

Articles On GuruFocus.com
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 01 2011 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
Auxilium Pharmaceuticals Inc. (AUXL) CFO James E Fickenscher sells 4,000 Shares Sep 16 2009 
Auxilium Pharmaceuticals Inc. (AUXL) CFO James E Fickenscher sells 4,000 Shares Sep 10 2009 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 10 2009 
Auxilium Pharmaceuticals Inc. Reports Operating Results (10-Q) May 08 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial